KR20110130454A - 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 - Google Patents

리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 Download PDF

Info

Publication number
KR20110130454A
KR20110130454A KR1020117023001A KR20117023001A KR20110130454A KR 20110130454 A KR20110130454 A KR 20110130454A KR 1020117023001 A KR1020117023001 A KR 1020117023001A KR 20117023001 A KR20117023001 A KR 20117023001A KR 20110130454 A KR20110130454 A KR 20110130454A
Authority
KR
South Korea
Prior art keywords
peg
aqueous solution
composition
active agent
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117023001A
Other languages
English (en)
Korean (ko)
Inventor
바그와티 피. 카브라
말레이 고쉬
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20110130454A publication Critical patent/KR20110130454A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117023001A 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 Ceased KR20110130454A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
US61/156,922 2009-03-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032103A Division KR20160135372A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Publications (1)

Publication Number Publication Date
KR20110130454A true KR20110130454A (ko) 2011-12-05

Family

ID=42678800

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117023001A Ceased KR20110130454A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
KR1020167032103A Abandoned KR20160135372A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167032103A Abandoned KR20160135372A (ko) 2009-03-03 2010-03-03 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물

Country Status (12)

Country Link
US (2) US20100227905A1 (https=)
EP (1) EP2403335B1 (https=)
JP (1) JP5583146B2 (https=)
KR (2) KR20110130454A (https=)
CN (1) CN102340991B (https=)
AU (1) AU2010221369B2 (https=)
BR (1) BRPI1012302A2 (https=)
CA (1) CA2753690A1 (https=)
ES (1) ES2508290T3 (https=)
MX (1) MX2011008731A (https=)
WO (1) WO2010101992A1 (https=)
ZA (1) ZA201105505B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US20120022149A1 (en) * 2010-07-21 2012-01-26 Chowhan Masood A Pharmaceutical composition with enhanced solubility characteristics
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20140160236A1 (en) * 2011-07-29 2014-06-12 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
RU2646098C2 (ru) * 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
CN107635545A (zh) 2015-01-27 2018-01-26 约翰霍普金斯大学 用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
ES2992596T3 (en) * 2019-11-28 2024-12-16 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
CA2226348A1 (en) * 1996-05-07 1997-11-13 Takashi Ikari Ophthalmic preparations
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
JP2009521510A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
JP2010534201A (ja) * 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤

Also Published As

Publication number Publication date
EP2403335A4 (en) 2012-08-29
WO2010101992A1 (en) 2010-09-10
ES2508290T3 (es) 2014-10-16
CN102340991A (zh) 2012-02-01
US20130137741A1 (en) 2013-05-30
AU2010221369A1 (en) 2011-08-25
CA2753690A1 (en) 2010-09-10
MX2011008731A (es) 2011-09-29
EP2403335A1 (en) 2012-01-11
JP2012519694A (ja) 2012-08-30
US20100227905A1 (en) 2010-09-09
CN102340991B (zh) 2014-02-26
AU2010221369B2 (en) 2014-03-13
EP2403335B1 (en) 2014-08-20
ZA201105505B (en) 2013-10-30
KR20160135372A (ko) 2016-11-25
JP5583146B2 (ja) 2014-09-03
BRPI1012302A2 (pt) 2015-09-22

Similar Documents

Publication Publication Date Title
KR20110130454A (ko) 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
AU2010221438B2 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US20070149593A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US9968603B2 (en) Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US8912236B2 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CN101842080A (zh) 非水的水混溶性物质作为药物递送的载体
ES2863601T3 (es) Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo
KR20100051811A (ko) 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
US20070173538A1 (en) PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
KR102474404B1 (ko) 다중 표적 억제제의 현탁액 조성물
WO2025078308A1 (en) Gel formulation for topical ocular use
TW202038928A (zh) 多目標抑製劑的懸浮液組合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160108

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160108

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160829

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160329

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20161020

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160928

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160829

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160329

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160108

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161117

PJ0201 Trial against decision of rejection

Patent event date: 20161117

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20160829

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180131

Appeal identifier: 2016101006505

Request date: 20161117

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101006505; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161117

Effective date: 20180131

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180131

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20161117

Decision date: 20180131

Appeal identifier: 2016101006505